Gregory J Wehner1, Linyuan Jing2,3, Christopher M Haggerty2,3, Jonathan D Suever2,3, Joseph B Leader3, Dustin N Hartzel3, H Lester Kirchner3, Joseph N A Manus3, Nick James4, Zina Ayar5, Patrick Gladding4, Christopher W Good6, John G F Cleland7, Brandon K Fornwalt2,3,6,8. 1. Department of Biomedical Engineering, University of Kentucky, Lexington, KY, USA. 2. Department of Imaging Science and Innovation, Geisinger, Danville, PA, USA. 3. Biomedical and Translational Informatics Institute, Geisinger, Danville, PA, USA. 4. Department of Cardiology, Waitemata District Health Board, Auckland, New Zealand. 5. Clinical Informatics Service, Waitemata District Health Board, Auckland, New Zealand. 6. Heart Institute, Geisinger, Danville, PA, USA. 7. Robertson Centre for Biostatistics and Clinical Trials, University of Glasgow and National Heart & Lung Institute, Imperial College London, London, UK. 8. Department of Radiology, Geisinger, 100 North Academy Avenue, Danville 17822-4400, PA, USA.
Abstract
AIMS: We investigated the relationship between clinically assessed left ventricular ejection fraction (LVEF) and survival in a large, heterogeneous clinical cohort. METHODS AND RESULTS: Physician-reported LVEF on 403 977 echocardiograms from 203 135 patients were linked to all-cause mortality using electronic health records (1998-2018) from US regional healthcare system. Cox proportional hazards regression was used for analyses while adjusting for many patient characteristics including age, sex, and relevant comorbidities. A dataset including 45 531 echocardiograms and 35 976 patients from New Zealand was used to provide independent validation of analyses. During follow-up of the US cohort, 46 258 (23%) patients who had undergone 108 578 (27%) echocardiograms died. Overall, adjusted hazard ratios (HR) for mortality showed a u-shaped relationship for LVEF with a nadir of risk at an LVEF of 60-65%, a HR of 1.71 [95% confidence interval (CI) 1.64-1.77] when ≥70% and a HR of 1.73 (95% CI 1.66-1.80) at LVEF of 35-40%. Similar relationships with a nadir at 60-65% were observed in the validation dataset as well as for each age group and both sexes. The results were similar after further adjustments for conditions associated with an elevated LVEF, including mitral regurgitation, increased wall thickness, and anaemia and when restricted to patients reported to have heart failure at the time of the echocardiogram. CONCLUSION: Deviation of LVEF from 60% to 65% is associated with poorer survival regardless of age, sex, or other relevant comorbidities such as heart failure. These results may herald the recognition of a new phenotype characterized by supra-normal LVEF. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: We investigated the relationship between clinically assessed left ventricular ejection fraction (LVEF) and survival in a large, heterogeneous clinical cohort. METHODS AND RESULTS: Physician-reported LVEF on 403 977 echocardiograms from 203 135 patients were linked to all-cause mortality using electronic health records (1998-2018) from US regional healthcare system. Cox proportional hazards regression was used for analyses while adjusting for many patient characteristics including age, sex, and relevant comorbidities. A dataset including 45 531 echocardiograms and 35 976 patients from New Zealand was used to provide independent validation of analyses. During follow-up of the US cohort, 46 258 (23%) patients who had undergone 108 578 (27%) echocardiograms died. Overall, adjusted hazard ratios (HR) for mortality showed a u-shaped relationship for LVEF with a nadir of risk at an LVEF of 60-65%, a HR of 1.71 [95% confidence interval (CI) 1.64-1.77] when ≥70% and a HR of 1.73 (95% CI 1.66-1.80) at LVEF of 35-40%. Similar relationships with a nadir at 60-65% were observed in the validation dataset as well as for each age group and both sexes. The results were similar after further adjustments for conditions associated with an elevated LVEF, including mitral regurgitation, increased wall thickness, and anaemia and when restricted to patients reported to have heart failure at the time of the echocardiogram. CONCLUSION: Deviation of LVEF from 60% to 65% is associated with poorer survival regardless of age, sex, or other relevant comorbidities such as heart failure. These results may herald the recognition of a new phenotype characterized by supra-normal LVEF. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Lars H Lund; Brian Claggett; Jiankang Liu; Carolyn S Lam; Pardeep S Jhund; Giuseppe M Rosano; Karl Swedberg; Salim Yusuf; Christopher B Granger; Marc A Pfeffer; John J V McMurray; Scott D Solomon Journal: Eur J Heart Fail Date: 2018-02-12 Impact factor: 15.534
Authors: John G F Cleland; John R Teerlink; Beth A Davison; Ahmad Shoaib; Marco Metra; Stefanie Senger; Olga Milo; Gad Cotter; Robert C Bourge; John D Parker; Guillaume Jondeau; Henry Krum; Christopher M O'Connor; Guillermo Torre-Amione; Dirk J van Veldhuisen; John J V McMurray Journal: Eur J Heart Fail Date: 2017-03-10 Impact factor: 15.534
Authors: John S Gottdiener; Robyn L McClelland; Robert Marshall; Lynn Shemanski; Curt D Furberg; Dalane W Kitzman; Mary Cushman; Joseph Polak; Julius M Gardin; Bernard J Gersh; Gerard P Aurigemma; Teri A Manolio Journal: Ann Intern Med Date: 2002-10-15 Impact factor: 25.391
Authors: Jeptha P Curtis; Seth I Sokol; Yongfei Wang; Saif S Rathore; Dennis T Ko; Farid Jadbabaie; Edward L Portnay; Stephen J Marshalko; Martha J Radford; Harlan M Krumholz Journal: J Am Coll Cardiol Date: 2003-08-20 Impact factor: 24.094
Authors: Justin T Huntington; Mathew Butterfield; James Fisher; Daniel Torrent; Mark Bloomston Journal: Am J Cancer Res Date: 2013-11-01 Impact factor: 6.166
Authors: John G F Cleland; Karina V Bunting; Marcus D Flather; Douglas G Altman; Jane Holmes; Andrew J S Coats; Luis Manzano; John J V McMurray; Frank Ruschitzka; Dirk J van Veldhuisen; Thomas G von Lueder; Michael Böhm; Bert Andersson; John Kjekshus; Milton Packer; Alan S Rigby; Giuseppe Rosano; Hans Wedel; Åke Hjalmarson; John Wikstrand; Dipak Kotecha Journal: Eur Heart J Date: 2018-01-01 Impact factor: 29.983
Authors: Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer Journal: Eur Heart J Date: 2016-05-20 Impact factor: 29.983
Authors: Christopher M Haggerty; Brandon K Fornwalt; Alvaro E Ulloa Cerna; Linyuan Jing; Christopher W Good; David P vanMaanen; Sushravya Raghunath; Jonathan D Suever; Christopher D Nevius; Gregory J Wehner; Dustin N Hartzel; Joseph B Leader; Amro Alsaid; Aalpen A Patel; H Lester Kirchner; John M Pfeifer; Brendan J Carry; Marios S Pattichis Journal: Nat Biomed Eng Date: 2021-02-08 Impact factor: 25.671
Authors: Xiaoyan Zhang; Alvaro E Ulloa Cerna; Joshua V Stough; Yida Chen; Brendan J Carry; Amro Alsaid; Sushravya Raghunath; David P vanMaanen; Brandon K Fornwalt; Christopher M Haggerty Journal: Int J Cardiovasc Imaging Date: 2022-02-24 Impact factor: 2.357
Authors: Akhil Vaid; Kipp W Johnson; Marcus A Badgeley; Sulaiman S Somani; Mesude Bicak; Isotta Landi; Adam Russak; Shan Zhao; Matthew A Levin; Robert S Freeman; Alexander W Charney; Atul Kukar; Bette Kim; Tatyana Danilov; Stamatios Lerakis; Edgar Argulian; Jagat Narula; Girish N Nadkarni; Benjamin S Glicksberg Journal: JACC Cardiovasc Imaging Date: 2021-10-13
Authors: Naomi Dempsey; Amanda Rosenthal; Nitika Dabas; Yana Kropotova; Marc Lippman; Nanette H Bishopric Journal: Breast Cancer Res Treat Date: 2021-06-11 Impact factor: 4.872
Authors: Michael D Maile; Michael R Mathis; Robert H Habib; Thomas A Schwann; Milo C Engoren Journal: Heart Lung Circ Date: 2021-01-27 Impact factor: 2.838